Table 1.
Baseline characteristics of patients who performed serial CPET at 6 and 12 months after MCS (n = 105)
| Baseline characteristics | |
|---|---|
| Gender, male (%) | 70 (67%) |
| Age at MCS implantation (years, mean ± SD) II | 50 ± 12 |
| Device type | |
| HM‐II (%) | 75 (71.4%) |
| HVAD (%) | 22 (21%) |
| HM3 (%) | 8 (7.6%) |
| Aetiology | |
| Dilated | 55 (52%) |
| Ischaemic | 35 (33%) |
| Myocarditis | 1 (1%) |
| Hypertrophic | 1 (1%) |
| Peripartum | 1 (1%) |
| Congenital | 1 (1%) |
| Toxic | 5 (5%) |
| Other | 6 (6%) |
| INTERMACS profile | |
| 1 with temporary support | 20 (19%) |
| 1 without temporary support | 1 (1%) |
| 2 | 47 (45%) |
| 3 | 30 (29%) |
| 4 | 6 (6%) |
| 6 | 1 (1%) |
| Hospital duration, days (mean ± SD) | 48 ± 22 |
HM‐II, HeartMate‐II; HM3, HeartMate 3; HVAD, HeartWare; INTERMACS, Inter‐agency Registry for Mechanically Assisted Circulatory Support; II MCS, mechanical circulatory support.